Glenmark Pharmaceuticals Ltd
About
The late Gracias Saldanha founded Glenmark in 1977 to develop and market generic formulations. These formulations can now be spotted in geographies like the US, Europe, and Latin America. Its manufacturing facilities span the globe with 14 facilities spread across India, the US, Argentina, and the Czech Republic and focus on producing niche offerings, particularly in the fields of dermatology, respiration, and oncology. Other Glenmark products include those in the therapeutic areas of cardiovascular diseases and diabetes. Its first molecule research centre opened in Mahape, India, in the year 2000, after which it opened a biologics research centre in 2006 in Switzerland. Today, Glenmark collaborates with other companies, such as Forest Laboratories, for its small and biologics molecular research.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 13246 5.3% | 12580 0.8% | 12483 11.2% | 11228 4.9% | 10705 3.9% | 10299 14.0% | 9032 -5.7% | 9576 24.0% | 7722 11.2% | 6943 14.9% | 6044 19.9% | 5040 26.0% | 3999 27.0% | 3149 23.0% | 2560 3.4% | 2477 - |
| Net Operating Income (INR Cr) | 11813 1.98% | 11583 -5.86% | 12305 12.44% | 10944 2.85% | 10641 7.86% | 9865 8.72% | 9074 -0.05% | 9079 20.07% | 7562 13.18% | 6681 11.25% | 6005 19.81% | 5012 24.67% | 4021 36.34% | 2949 18.89% | 2480 18.88% | 2086 5.61% |
| Profit (INR Cr) | -1502 - | 297 -68.4% | 942 -2.9% | 970 25.0% | 776 -16.1% | 925 15.1% | 804 -27.5% | 1109 49.2% | 743 254.6% | 210 -61.4% | 542 -12.5% | 620 34.7% | 460 1.6% | 453 39.7% | 324 69.3% | 192 - |
| Assets (INR Cr) | 9619 -35.2% | 14845 9.5% | 13553 10.7% | 12247 7.7% | 11368 12.1% | 10143 3.4% | 9805 6.0% | 9248 20.2% | 7694 34.9% | 5705 -9.7% | 6316 12.0% | 5637 18.3% | 4764 13.9% | 4182 -1.3% | 4238 14.7% | 3696 - |
| Net Worth (INR Cr) | 7848 -17.2% | 9474 4.3% | 9087 28.6% | 7065 16.4% | 6071 8.3% | 5605 8.6% | 5163 14.9% | 4493 23.8% | 3630 103.5% | 1784 -40.2% | 2983 8.0% | 2763 15.1% | 2402 17.9% | 2037 -13.5% | 2355 47.4% | 1598 5.3% |
| Employee Cost (INR Cr) | 2868 10.3% | 2601 6.3% | 2447 4.4% | 2344 3.9% | 2255 9.7% | 2056 9.8% | 1872 14.1% | 1641 19.1% | 1378 13.7% | 1213 18.2% | 1026 31.1% | 783 24.5% | 629 23.3% | 510 75.9% | 290 6.5% | 272 - |
| Interest Cost (INR Cr) | 516 | 349 | 298 | 353 | 377 | 335 | 286 | 237 | 179 | 190 | 189 | 160 | 147 | 160 | 166 | 146 |
| Cash & Bank Balance (INR Cr) | 1659 | 1160 | 1412 | 1139 | 1111 | 938 | 1235 | 1058 | 857 | 776 | 801 | 607 | 322 | 196 | 107 | 71 |
| Total Debt (INR Cr) | 1231 | 4608 | 3962 | 4986 | 4869 | 4449 | 4639 | 4724 | 3988 | 3800 | 3267 | 2765 | 2245 | 2108 | 1869 | 2094 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | - | 2.4% | 7.5% | 8.6% | 7.3% | 9.0% | 8.9% | 11.6% | 9.6% | 3.0% | 9.0% | 12.3% | 11.5% | 14.4% | 12.7% | 7.7% |
| Profit As % Of Assets | - | 2.0% | 7.0% | 7.9% | 6.8% | 9.1% | 8.2% | 12.0% | 9.7% | 3.7% | 8.6% | 11.0% | 9.7% | 10.8% | 7.7% | 5.2% |
| Profit As % Of Networth | - | 3.1% | 10.4% | 13.7% | 12.8% | 16.5% | 15.6% | 24.7% | 20.5% | 11.8% | 18.2% | 22.4% | 19.2% | 22.3% | 13.8% | 12.0% |
| Interest Cost to EBITDA % | 175.3% | 40.2% | 14.5% | 16.9% | 22.2% | 21.1% | 17.7% | 12.1% | 12.5% | 18.5% | 17.3% | 15.8% | 20.5% | 27.1% | 26.7% | 43.1% |
| Debt to Equity Ratio | 0.16 | 0.49 | 0.44 | 0.71 | 0.80 | 0.79 | 0.90 | 1.05 | 1.10 | 2.13 | 1.10 | 1.00 | 0.93 | 1.03 | 0.79 | 1.31 |
| RONW | - | 7.4% | 14.4% | 14.8% | 13.3% | 15.2% | 16.7% | 27.3% | 27.5% | 11.1% | 18.9% | 24.1% | 20.7% | 20.7% | 16.7% | 12.4% |
| ROCE | 12.1% | 9.8% | 15.8% | 14.7% | 13.7% | 14.7% | 14.8% | 20.4% | 18.3% | 15.3% | 14.8% | 17.3% | 14.2% | 15.3% | 13.9% | 13.4% |